ATE366576T1 - Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6- - Google Patents
Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-Info
- Publication number
- ATE366576T1 ATE366576T1 AT04704575T AT04704575T ATE366576T1 AT E366576 T1 ATE366576 T1 AT E366576T1 AT 04704575 T AT04704575 T AT 04704575T AT 04704575 T AT04704575 T AT 04704575T AT E366576 T1 ATE366576 T1 AT E366576T1
- Authority
- AT
- Austria
- Prior art keywords
- 1lamda
- dioxo
- trifluoromethyl
- bis
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03002134 | 2003-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366576T1 true ATE366576T1 (de) | 2007-08-15 |
Family
ID=32798734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04704575T ATE366576T1 (de) | 2003-01-31 | 2004-01-23 | Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6- |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7160881B2 (de) |
| EP (1) | EP1592428B1 (de) |
| JP (1) | JP5026702B2 (de) |
| KR (1) | KR100700421B1 (de) |
| CN (1) | CN100562320C (de) |
| AR (1) | AR042980A1 (de) |
| AT (1) | ATE366576T1 (de) |
| AU (1) | AU2004208483B8 (de) |
| BR (1) | BRPI0406702A (de) |
| CA (1) | CA2514037C (de) |
| CL (1) | CL2004000150A1 (de) |
| CO (1) | CO5580750A2 (de) |
| DE (1) | DE602004007486T2 (de) |
| ES (1) | ES2290666T3 (de) |
| GT (1) | GT200400009A (de) |
| HR (1) | HRP20050664A2 (de) |
| IL (1) | IL169600A (de) |
| MX (1) | MXPA05008171A (de) |
| MY (1) | MY135785A (de) |
| NO (1) | NO20053431L (de) |
| NZ (1) | NZ541243A (de) |
| PA (1) | PA8594601A1 (de) |
| PE (1) | PE20040944A1 (de) |
| PL (1) | PL378404A1 (de) |
| RU (1) | RU2330022C2 (de) |
| TW (1) | TWI293294B (de) |
| WO (1) | WO2004067007A1 (de) |
| ZA (1) | ZA200505567B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1776342B1 (de) | 2004-07-06 | 2011-03-02 | F. Hoffmann-La Roche AG | Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten |
| KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
| AU2010288502B2 (en) * | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
| CN103755592A (zh) * | 2013-12-30 | 2014-04-30 | 镇江圣安医药有限公司 | (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| JP3071467B2 (ja) | 1993-12-29 | 2000-07-31 | メルク シヤープ エンド ドーム リミテツド | 置換モルホリン誘導体およびその治療剤としての使用 |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| DK1394150T3 (da) | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| CN100398106C (zh) * | 2001-04-23 | 2008-07-02 | 弗·哈夫曼-拉罗切有限公司 | Nk-1受体拮抗剂对抗良性前列腺增生的用途 |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
-
2004
- 2004-01-23 AT AT04704575T patent/ATE366576T1/de active
- 2004-01-23 ES ES04704575T patent/ES2290666T3/es not_active Expired - Lifetime
- 2004-01-23 JP JP2005518353A patent/JP5026702B2/ja not_active Expired - Fee Related
- 2004-01-23 NZ NZ541243A patent/NZ541243A/en unknown
- 2004-01-23 KR KR1020057014025A patent/KR100700421B1/ko not_active IP Right Cessation
- 2004-01-23 DE DE602004007486T patent/DE602004007486T2/de not_active Expired - Lifetime
- 2004-01-23 WO PCT/EP2004/000547 patent/WO2004067007A1/en active IP Right Grant
- 2004-01-23 BR BR0406702-9A patent/BRPI0406702A/pt not_active Application Discontinuation
- 2004-01-23 CN CN200480003306.7A patent/CN100562320C/zh not_active Expired - Fee Related
- 2004-01-23 EP EP04704575A patent/EP1592428B1/de not_active Expired - Lifetime
- 2004-01-23 AU AU2004208483A patent/AU2004208483B8/en not_active Ceased
- 2004-01-23 PL PL378404A patent/PL378404A1/pl unknown
- 2004-01-23 RU RU2005127216/04A patent/RU2330022C2/ru not_active IP Right Cessation
- 2004-01-23 MX MXPA05008171A patent/MXPA05008171A/es active IP Right Grant
- 2004-01-23 CA CA2514037A patent/CA2514037C/en not_active Expired - Fee Related
- 2004-01-27 US US10/766,122 patent/US7160881B2/en not_active Expired - Fee Related
- 2004-01-27 TW TW093101746A patent/TWI293294B/zh active
- 2004-01-28 PE PE2004000110A patent/PE20040944A1/es not_active Application Discontinuation
- 2004-01-28 PA PA20048594601A patent/PA8594601A1/es unknown
- 2004-01-29 GT GT200400009A patent/GT200400009A/es unknown
- 2004-01-30 CL CL200400150A patent/CL2004000150A1/es unknown
- 2004-01-30 MY MYPI20040288A patent/MY135785A/en unknown
- 2004-01-30 AR ARP040100284A patent/AR042980A1/es unknown
-
2005
- 2005-07-07 IL IL169600A patent/IL169600A/en unknown
- 2005-07-11 ZA ZA200505567A patent/ZA200505567B/en unknown
- 2005-07-14 NO NO20053431A patent/NO20053431L/no not_active Application Discontinuation
- 2005-07-18 CO CO05070753A patent/CO5580750A2/es not_active Application Discontinuation
- 2005-07-21 HR HR20050664A patent/HRP20050664A2/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60209704D1 (de) | Neue kristallforme von azithromycin | |
| ATE369330T1 (de) | O-desmethyl-venlafaxine succinat salz | |
| DE60321324D1 (de) | Sulfonylaminoderivate als neue inhibitoren von histondeacetylase | |
| NL1027811A1 (nl) | Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1. | |
| DE60328671D1 (de) | Neue aminobenzamidderivate | |
| ATE497953T1 (de) | Thiazolderivate als modulatoren des cannabinoidrezeptors | |
| DE60215848D1 (de) | 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren | |
| DE60310731D1 (de) | Neue, von noraporphin abgeleitete moleküle | |
| ATE403650T1 (de) | 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren | |
| NO20033203L (no) | Terapeutiske heterocykliske forbindelser | |
| CY2009001I2 (el) | Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης | |
| ATE510556T1 (de) | Verwendung von erythropoietin | |
| DK1411926T3 (da) | Integrininhibitorer til behandling af öjensygdomme | |
| DE502004011575D1 (de) | Verwendung von Dioldimerfettsäureestern | |
| IS2212B (is) | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide | |
| NO20040404L (no) | 2- (3,5-bis-trifluorometyl-fenyl) - N - [6-(1,1-diokso-1lam bda6-tiomorfolin-4-yl) - 4 - (2-metyl- eller 4-fluor-2-metylsubstituert) fenyl-pyridin-3-yl] -N-metyl-isobutyrami. | |
| ATE444290T1 (de) | Oxazolderivate von tetracyclinen | |
| DE60224221D1 (de) | Aminotetralinderivate, antagonisten von muscarinrezeptoren | |
| DE60227828D1 (de) | E von schmelzkleber | |
| DE60201256D1 (de) | Elektrooptischer wanderwellenmodulator | |
| ATE366576T1 (de) | Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6- | |
| NO20042613L (no) | Ny anvendelse for behandling av gastroosofagial refluks | |
| ATE344270T1 (de) | Neue 3-decladinosyl-9a-n-carbamoyl- und 9a-n- thiocarbamoylderivate von 9-deoxo-9-dihydro-9a- aza-9a-homoerythromycin a | |
| ATE342890T1 (de) | Polymorph v von torasemid | |
| ATE499348T1 (de) | Stabiler polymorph von bifeprunoxmesilat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1592428 Country of ref document: EP |